Last checked at 19 Jun 2019 07:00
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Board Change
Appointment of Mary Tavener as Non-Executive Director
19 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that Mary Tavener will join the Board of Allergy Therapeutics as a Non-Executive Director with immediate effect. Mary will also join the Audit Committee of the Board and will work closely with the current chair Stephen Smith in anticipation of her succeeding Stephen as chair of the committee after the Group publishes its final results for the year ended 30 June 2019 in September.
Mary has extensive experience in the healthcare sector, having spent more than 19 years as Chief Financial Officer and Board member of AIM listed Advanced Medical Solutions ("AMS"). At AMS, Mary was responsible for strategy and risk management, finance, operations, regulatory, and legal. During her tenure through to the end of 2018, AMS delivered 15 consecutive years of growth, listed on AIM, and successfully conducted several transformational M&A deals. Mary is a Fellow of the Chartered Institute of Management Accountants (FCMA) and a Fellow of the Association of Corporate Treasurers (FCT). Prior to joining AMS, Mary was the Group Financial Controller of BTP plc.
Commenting on the appointment, Peter Jensen, Chairman of Allergy Therapeutics, said: "I am delighted to announce Mary's appointment and welcome her to the Board. Mary has an excellent track record and an impressive breadth of executive experience, and we look forward to the invaluable and trusted perspective she will bring to the Board."
Commenting on her appointment, Mary Tavener said: "Allergy Therapeutics has an excellent growth story since its formation as a small spinout from SmithKline Beecham in 1999. The business today has a broad range of assets in clinical development, a global presence across 23 markets, over 500 employees, and has achieved a 10% CAGR over the last 19 years as well as significant commercial success. I look forward to working with the Board to further develop Allergy's leading position in the allergen immunotherapy sector."
Additional Information
In accordance with the AIM Rules, the following information required to be disclosed in relation to Mary Tavener is set out below. Other than this information, there is no further information required to be disclosed under paragraph (g) of Schedule Two of the AIM Rules.
Full name and age
Mary Geraldine Tavener, 57 years old
Current Directorships | Past Directorships in the previous five years |
|
|
Cuddington & Sandiway Parish Playing Fields Association Limited | Advanced Healthcare Systems Limited |
| Advanced Medical Solutions (Uk) Limited |
| Advanced Medical Solutions Group plc |
| Advanced Medical Solutions Limited |
| Advanced Medical Solutions (Plymouth) Limited |
| AMS Trustee Company Limited |
| Innovative Technologies Limited |
| Medlogic Global Holdings Limited |
| Advanced Medical Solutions (Europe) Limited |
| Advanced Healthcare Systems Limited |
| Advanced Medical Solutions (UK) Limited |
| Advanced Medical Solutions Group plc |
|
|
|
|
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Erik Anderson, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Nicholas Brown / Olivia Manser
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Other adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved double digit compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.